GgoogleGB first seen 5 h ago, last 4 h ago, peak #8
Mounjaro rival eloralintide shows promise in weight loss study
Original: mounjaro and eloralintide weight loss study
New study results for eloralintide, an injectable weight-loss drug developed by Eli Lilly, are drawing attention alongside Mounjaro. The Guardian describes the drug as a potential 'Godzilla' of weight-loss treatments, suggesting it could deliver weight reduction plus other important health benefits. Discussion is focused on how it might compete with existing GLP-1 drugs like Mounjaro and what additional health effects it may offer.
Why now: Fresh clinical study results position eloralintide as a possible competitor to Mounjaro in the fast-growing weight-loss drug market.
Eli LillyeloralintideMounjaroThe Guardian
Rank over time, top of the chart is #1. 5 snapshots from 5 h ago to 4 h ago.
Evidence
- Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds · USA Today
- People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug · NBC News
- ‘Godzilla’ of weight-loss drugs could provide other important health benefits · The Guardian
API: https://socialmediatrends-api.osmike.com/v1/trends/597013